eiwitvertering bij gezonde mensen normal digestion
Conditions
Interventions
Participants will ingest three 400-mL test foods containing 20 g pea protein:
- Protein in suspension: 5% (5 g/100g) protein suspension unheated
- Protein in suspension: 5% (5 g/100g) protein suspens
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Male • 18 - 55 yr old • In self-reported health • BMI between 18,5 and 25kg/m2
Exclusion criteria
Exclusion criteria: • Pea protein allergy (self-reported) • Disorders of the upper ingestive tract resulting in difficulties chewing/swallowing. • Unexplained weight change >5 kg in the month within 1 month prior to the pre-study screeningsday • Gastric disorders or regular gastric complaints, heart burn for example • Use of proton pump inhibitors or other medication which alters the normal functioning of the stomach • Use of a medical drug use that influences the GI tract*s normal function, e.g. the motility, pH etc: among others use of proton pump inhibitors, antacids, anti-depressants etc. • Use of a medical drug use that influence the GI tract*s microbiota: antibiotic use within 1 months prior to the pre-study screenings day • use of recreational drugs within 1 month prior to the pre-study screenings day • alcohol consumption of more than 14 glasses/week • Smoking (>2 sigarettes a week) • Having a contra-indication to MRI scanning (including, but not limited to): * Pacemakers and defibrillators * Intraorbital or intraocular metallic fragments * Ferromagnetic implants * Claustrofobic • Not wanting information at unexpected findings • Use of protein supplements during the study • Following a medical diet • Being an employee or student of the Division of Human Nutrition and health •Having donated blood in the two months preceding the first visit •Hb value below 8.4 mmol/L (as measured with finger-prick method)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastric content volume over time, postprandial plasma amino-acid concentrations. | — |
Secondary
| Measure | Time frame |
|---|---|
| Intra-gastric processes (coagulation, emulsion stability), MRI markers (T2, MT) | — |
Countries
Netherlands
Outcome results
None listed